Full Press Release Details
The PRISM clinical trial assesses 4D-150 (4D Molecular Therapeutics) in adults with neovascular age-related macular degeneration, also known as wet AMD.
At the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting, Christine Kay, MD, of Vitreoretinal Associates in Gainesville, Florida, shared an update from the PRISM clinical trial. Dr. Kay is a vitreoretinal surgeon and inherited retinal disease specialist. She is actively involved as an investigator in multiple clinical trials at Vitreo Retinal Associates, and presented data on behalf of 4D Molecular Therapeutics (4DMT).
"The PRISM trial is a phase 1/2 clinical trial, looking at a gene therapy for wet [neovascular] macular degeneration," Dr. Kay said. "The 4D-150 vector is designed for intravitreal injection, single delivery, and it is optimized for intravitreal injection with specific retinal tropism, meaning increased transduction to retinal cells. It's also optimized to be able to invade the vitreoretinal barricades. The 4D-150 cassette is a dual vector, dual transgene cassette encoding both aflibercept as well as a micro-mRNA sequence inhibiting VEGF-C."
Dr. Kay provided an interim update on the phase 2b population extension study, which examined patients with severe disease and more recently-diagnosed patients who had seen less progression. To learn more, watch the full video and hear Dr. Kay's full summary of the results, including her analysis of the reduction in treatment burden.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Related Content
Redefining the possible: MCO-010’s 3-year retinal data
Could FLIO predict how fast geographic atrophy will grow?
Vaccinated patients show markedly lower risk of new-onset idiopathic uveitis
Revakinagene taroretcel-lwey for MacTel: Charles Wykoff, MD, PhD, on a year of real-world experience
Detecting peripheral retinal lesions in children with myopia
Latest CME
Retina Updates in Montréal
July 16-17, 2026
PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence
Solange Peters, MD, PhD; Benjamin P. Levy, MD; Tony S.K. Mok, MD, BMSc, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO; Maurice Pérol, MD
PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways
Solange Peters, MD, PhD; Stephanie McDonald, FNP-BC, AOCNP; Antonio Passaro, MD, PhD; Jacob Sands, MD
Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
SriniVas Sadda, MD, FARVO; Nathan Steinle, MD
Interventional Dry Eye: A Stepwise Treatment & Management Approach
Mark Schaeffer, OD, FAAO; Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO, FAAOMS; Selina R. McGee, OD, FAAO
(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
Mark R. Barakat, MD, FASRS; David Eichenbaum, MD, FASRS
(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment
Dilsher Dhoot, MD, FASRS; Jordana G. Fein, MD, MS; Deep Parikh, MD; Xiao-Yi (Ellie) Zhou, MD
(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice
Dante Pieramici, MD, FASRS; Dean Eliott, MD; Robin A. Vora, MD; Charles C. Wykoff, MD, PhD, FASRS
(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP
Ramiro Maldonado, MD; Rebecca Nelson, MS, CGC; Robert A. Sisk, MD, FACS, FASRS
(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management
David Almeida, MD, PhD, MBA; Margaret A. Chang, MD, MS; Arshad M. Khanani, MD, MA, FASRS; Jessica Randolph, MD
Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO
SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS
(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis
Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO
Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
John Kitchens, MD; Michael W. Stewart, MD
Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California
Dilsher S. Dhoot, MD, FASRS
Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro
Deep Parikh, MD
When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis
Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO
The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes
Uday Devgan, MD, FACS, FRCS
Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida
Carl J. Danzig, MD, FASRS